LIPFENDRA Explained: The First Oral PCSK9 Inhibitor for High(Bad) LDL Cholesterol

FDA Approves First Oral PCSK9 Inhibitor: Lipfendra Explained (Who It’s For, Cost, Benefits, Myths) Dr. Kulmeet Kundlas discusses the FDA approval of the first oral PCSK9 inhibitor, Lipfendra, as a potential game changer for patients with high cholesterol who can’t reach LDL targets with current therapy. He explains how cholesterol and lipoproteins (LDL and HDL) work, why lowering LDL reduces heart attack, stroke, PAD, and death risk, and how statins and PCSK9-targeting therapy lower LDL through different mechanisms. Lipfendra is a 20 mg once-daily pill taken on an empty stomach, priced at about $310/month, and can lower LDL by roughly 56–59% with minimal side effects (e.g., diarrhea, dizziness). FDA-approved use is as add-on therapy for patients on statins not at goal, familial hypercholesterolemia, and established ASCVD; it is not a statin replacement. He addresses common myths, emphasizes lifestyle changes, and outlines likely insurance and prescribing steps. 00:00 The FDA Just Approved This — Why It Matters 01:00 From $1,400 Injection to a $310 Pill 02:04 How Cholesterol Actually Works in Your Body 03:46 Statins vs. PCSK9: Two Different Targets 04:23 Why Lowering LDL Saves Lives (The Numbers) 05:42 Why I'm Excited — and Why It's Add-On, Not Replacement 06:44 Who's a Candidate — the Three Approved Groups 08:41 How to Take It: 20mg, Empty Stomach, Wait 30 Minutes 08:59 The Molecular Redesign That Made a Pill Possible 09:32 How Much It Lowers LDL — Cost and Side Effects 10:04 5 Myths I Need to Clear Up 12:07 Your Next Steps: The 4 Hoops